Four notes:
1. Second quarter revenue was up 53.5 percent year-over-year.
2. Proprietary products made up 64.5 percent of sales in the second quarter, compared to 47 percent during the same period last year.
3. The company saw increased expenses in the second quarter as the company prepares to launch new products under FDA review.
4. CEO Trent Northcutt said, “Our second quarter was another improved quarter for Aurora, as the company continued to get back to pre-COVID-19 revenue levels. That said, while pandemic headwinds still persist, we continue to be highly focused on developing more proprietary products.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
